The Northwell Health Constellation Gala Raises More Than $3.2M To Support Health Care Innovation In Manhattan

More than $3.2 million was raised at Northwell Health’s annual Constellation Gala, held November 19 at the Metropolitan Museum of Art. The event celebrates the philanthropic support that propels innovation throughout Northwell Health and transforms health care across the region. This year’s event was hosted by actress and comedian Cecily Strong and featured a musical performance by the Orchestra of St. Luke’s.

Proceeds will provide greater access to high-quality care by helping to advance services and programs across Manhattan at Lenox Hill Hospital, Manhattan Eye, Ear & Throat Hospital, Lenox Health Greenwich Village  – and soon, the Victoria and Lloyd Goldman Health Care Pavilion, a state-of-the-art outpatient care facility that is slated to open on the Upper East Side in 2026.

“We are committed to providing the most comprehensive, multispecialty care in Manhattan,” said Michael Dowling, president and CEO of Northwell Health. “The support of our donors propels us forward as we continue our pursuit of a future with improved health for all people in our care and in our communities.”

Serving Manhattan for more than 165 years, Lenox Hill Hospital has been a cornerstone in the community. Ranked one of the best hospitals in New York state by U.S. News & World Report, it offers world-class inpatient and surgical care as one of the most sophisticated hospitals in New York City, as well as seamless, convenient access to care at Manhattan Eye, Ear & Throat Hospital, Lenox Health Greenwich Village and more than 100 nearby outpatient practices.

The Constellation Gala also advances Northwell’s Outpacing the Impossible campaign, a comprehensive fundraising effort that supports Northwell’s promise to the people it serves. Since the start of the campaign in 2016, more than 207,000 donors have given more than $1.4 billion to improve hospitals and clinical programs, accelerate research, fund endowment and, raise support for several key areas of need, including expansion of care in Manhattan.

“The generosity of our donors stands as a testament to their belief in our mission,” said Brian T. Lally, president of the Northwell Foundation and chief development officer. “Philanthropic support has made a meaningful impact on Northwell’s ability to fuel groundbreaking research and teaching, bring new treatments and technologies and raise health for all.”

Leadership sponsors of the Constellation Gala included Margaret M. Crotty & Rory Riggs, Diane & Paul B. Guenther, Phyllis & William L. Mack, Donald Zucker & Barbara Hrbek Zucker, and Tara & Roy J. Zuckerberg.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”